MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of Suvaro®OD Tablet in Patients With Dyslipidemia

NCT06153433 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2023-12-01

No results posted yet for this study

Summary

The aim of study is to evaluate the efficacy and safety of the new generic formulation (rosuvastatin orally disintegrating tablet (SUVARO®ODT) in patients with dyslipidemia.

Conditions

Interventions

DRUG

Rosuvastatin Immediate-Release Tablet (IRT) 10mg

Rosuvastatin Immediate-Release Tablet (IRT) 10mg

DRUG

Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg

Rosuvastatin orally disintegrating tablet (SUVARO®ODT) 10mg

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Jung-Sun Kim · Division of Cardiology, Department of Internal Medicine, Yonsei Univerisity

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-06
Primary Completion
2024-07-31
Completion
2024-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06153433 on ClinicalTrials.gov